Jennison Associates
PVLA

Jennison Associates’s Palvella Therapeutics PVLA Stock Holding History

Jennison Associates’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$147M Buy
960,619
+320,008
+50% +$38.8M 0.09% 104
2026
Q1 		$79.9M Buy
640,611
+253,128
+65% +$26.4M 0.05% 162
2025
Q4 		$40.6M Buy
387,483
+280,573
+262% +$23.9M 0.02% 243
2025
Q3 		$6.7M Buy
+106,910
New +$4.77M ﹤0.01% 394

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Jennison Associates's PVLA Position: Q2 2026 in Review

Jennison Associates increased its Palvella Therapeutics (PVLA) stake by 50% in Q2 2026, buying an estimated $38.8M and bringing the position to 960,619 shares worth $147M. The position accounts for 0.09% of the portfolio, ranked #104.

Jennison Associates first reported a position in PVLA in Q3 2025 and has held it in 4 quarters since. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Jennison Associates held 960,619 shares of Palvella Therapeutics worth $147M as of Q2 2026.
  • Jennison Associates bought 320,008 Palvella Therapeutics shares in Q2 2026, an estimated $38.8M.
  • Palvella Therapeutics made up 0.09% of Jennison Associates's portfolio in Q2 2026, its #104 holding.
  • Jennison Associates first reported a position in Palvella Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.